Supplemental material
Open access
4,330
Views
14
CrossRef citations to date
0
Altmetric
Review
Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis
Zsombor ZrubkaDepartment of Health Economics, Corvinus University of Budapest, Budapest, Hungary;Doctoral School of Business and Management, Corvinus University of Budapest, Budapest, Hungaryhttps://orcid.org/0000-0002-1992-6087View further author information
, László GulácsiDepartment of Health Economics, Corvinus University of Budapest, Budapest, HungaryCorrespondence[email protected]
https://orcid.org/0000-0002-9285-8746View further author information
, https://orcid.org/0000-0002-9285-8746View further author information
Valentin BrodszkyDepartment of Health Economics, Corvinus University of Budapest, Budapest, Hungaryhttps://orcid.org/0000-0002-6095-2295View further author information
, Fanni RenczDepartment of Health Economics, Corvinus University of Budapest, Budapest, Hungaryhttps://orcid.org/0000-0001-9674-620XView further author information
, Rieke AltenRheumatology Research Center, Schlosspark-Klinik Charite, University Medicine Berlin, Berlin, Germanyhttps://orcid.org/0000-0002-3395-4412View further author information
, Zoltán SzekaneczDivision of Rheumatology, Department of Medicine, University of Debrecen Faculty of Medicine, Debrecen, Hungaryhttps://orcid.org/0000-0002-7794-6844View further author information
& Márta PéntekDepartment of Health Economics, Corvinus University of Budapest, Budapest, Hungary;Department of Rheumatology, Flór Ferenc County Hospital, Kistarcsa, Hungaryhttps://orcid.org/0000-0001-9636-6012View further author information
show all
Pages 537-549
|
Received 12 May 2019, Accepted 19 Jul 2019, Published online: 01 Aug 2019
Related Research Data
Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis
Source:
Taylor & Francis
Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis
Source:
Taylor & Francis
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.